Catalyst Event
Sino Biopharmaceutical Ltd (1177) · Other
From Akros SCHK HK-Korea Biotech Index (ASHKBIO)
5/29/2026, 12:00:00 AM
The company announced positive pivotal data from two Phase III clinical trials (B-Well 1 and B-Well 2) for bepirovirsen for the treatment of chronic hepatitis B, which were presented at the 2026 European Association for the Study of the Liver (EASL) Congress and published in the New England Journal of Medicine.
Korean Translation
만성 B형 간염 치료제 베피로비르센에 대한 두 건의 3상 임상시험(B-Well 1 및 B-Well 2)의 긍정적인 주요 데이터가 2026년 유럽간학회(EASL)에서 발표되고 뉴잉글랜드 저널 오브 메디슨에 게재되었음을 발표함.
Related Recent Events
Samchundang Pharm Co Ltd (000250) · Other
An extraordinary general meeting of shareholders to appoint a new outside director on June 30, 2026, scheduled. Low impact estimated as the appointment of an outside director is a routine administrative matter.
6/30/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
6/26/2026, 12:00:00 AM
United Laboratories International Holdings Ltd (3933) · Other
The Annual General Meeting is scheduled for June 23, 2026, to vote on financial statements and a potential 20% share issuance mandate which could dilute existing shareholdings; high importance due to potential dilution, scheduled.
6/23/2026, 12:00:00 AM
Aimed Bio Inc (0009K0) · Other
Stock price dropped approximately 18% on June 4, 2026, reportedly due to the expiration of a post-IPO lock-up period, which led to a significant volume of shares being sold by institutional investors.
6/4/2026, 12:00:00 AM
Celltrion Inc (068270) · Trading Issue
Bonus issue of 0.05 new shares per common share. The ex-rights date was June 4, 2026, with the new shares scheduled to be listed on June 30, 2026.
6/4/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Announcement that CLDN18.2 ADC IBI343 (arcotatug tavatecan) met Phase 3 primary endpoint in gastric cancer and NDA was accepted by NMPA; >10% price impact estimated due to first-in-class status expected
6/4/2026, 12:00:00 AM